SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW is trending as the community rallies around its deflationary meme coin status, highlighting its multichain functionality across Solana, BSC, CRO, and ETH (BASE) via Layerzero. Community members are enthusiastically chanting "caw caw caw" and emphasizing the coin's fully circulated supply and organic growth.

Bonk refers to a series of comic-style memes in which meme characters such as Doge and Cheems get hit on the head with bats, hammers and other heavy objects, accompanied by the “Bonk” sound effect and clipart. The original image that spawned the meme depicts a Shiba Inu, named Copper. Bonk brings this humor on-chain, transforming the classic meme into a tokenized digital movement powered by community and culture.

Copper Inu

Copper Inu ($COPPER) is trending amid community discussions about its chart patterns and potential for a breakout, particularly in relation to other tokens like $SOL and $BTC. Some users are pointing to its name as indicative of strength, while others express concerns about potential scams.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending amidst mixed sentiment, with some users expressing frustration and others anticipating a potential uptrend. Community members are actively discussing trading strategies, staking, and the impact of broader market trends on CRO's performance, while also referencing the meme coin $CAW.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, emphasizing its community-driven nature and long-term commitment with some holders staying strong for over a year. Conversations revolve around the playful "What's UpDog?" meme and promoting community engagement across various social media platforms to drive broader awareness.

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

RECALL CRYPTO is trending due to its recent ICO, with community members actively discussing its potential and current price action. High volume and new highs are fueling interest, though some caution against potential risks associated with new cryptocurrencies. The community is also comparing RECALL to other cryptocurrencies and exploring its potential within the broader crypto market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is gaining traction as traders discuss its low float and potential for a short squeeze, with comparisons being drawn to other Hong Kong-based stocks that have recently experienced significant gains. Community members are highlighting the company's regained NASDAQ compliance and a substantial contract exceeding its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential staking opportunities and meme coin integrations within its ecosystem. Conversations highlight Solana's strong setup and positive trend, with some anticipating a potential move towards new highs. Community members are also closely watching various meme coins built on Solana, such as $CAW and $UPDOG.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending amid community discussions around its financial strategies, particularly the recent Bitcoin exchange for Semnur shares and investments in Datavault AI, leaving some investors wary. Concerns are rising about potential shareholder dilution and whether these moves will truly benefit the company's core business and Semdexa's progress. The stock's volatility and high short interest are also fueling speculation about a potential short squeeze.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending due to its upcoming listing on Kraken, generating excitement about increased accessibility and potential price movement. The community is actively discussing staking strategies and accumulating more tokens in anticipation of further exchange listings and long-term gains. Some users also highlight recent institutional investments and positive on-chain data as bullish signals.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending as investors weigh the impact of rising electricity demand from AI and data centers, alongside discussions about the company's dividend and strategic direction. The community is actively debating Dominion's potential within the evolving energy landscape, particularly in light of both bullish Elliott Wave analyses projecting significant upside and concerns around debt and renewable energy investments. Several analysts have adjusted their ratings and price targets, contributing to the ongoing conversation around the utility stock.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.In after-hours trading on Wednesday, Mereo BioPharma dropped 38.8% to $1.80, while Ultragenyx fell 25.8% to $30.76.UX143 is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. It is being jointly developed by Ultragenyx and Mereo BioPharma.The Data Monitoring Committee (DMC) reviewed the Orbit study and found that the treatment’s safety profile appeared acceptable, recommending continuation to&nbsp;the final analysis.Final results from both the Orbit and Cosmic studies are expected to be released around the end of the year.The Orbit trial is testing UX143 in patients aged 5 to 25 with osteogenesis imperfecta, a condition characterized by brittle bones.&nbsp;Participants are receiving either the experimental treatment or a placebo, with the&nbsp;primary focus on&nbsp;the frequency of&nbsp;fractures.&nbsp;After the&nbsp;primary data is collected, all patients will move to open-label treatment.The Cosmic trial is running in parallel for children aged 2 to 7, comparing UX143 to standard bisphosphonate therapy.&nbsp;The study is also ongoing, with final results expected after patients&nbsp;have completed at least 18 months of treatment.On Stocktwits, retail sentiment for both&nbsp;<a href="https://stocktwits.com/symbol/MREO">Mereo BioPharma</a> and&nbsp;<a href="https://stocktwits.com/symbol/RARE">Ultragenyx</a> was tagged as ‘extremely bullish’ with ‘extremely high’ message volume.Some users&nbsp;suggested that the market was overreacting to the update from Mereo BioPharma and Ultragenyx, with one describing Mereo as a “good medium to long-term candidate” and another&nbsp;attributing the drop to a retail misunderstanding of standard clinical trial practices.<stembedurl>https://stocktwits.com/LogicalTrading/message/620417028</stembedurl><stembedurl>https://stocktwits.com/JCobb1/message/620403932</stembedurl>One comment noted that the final analysis will use a conventional 0.05 p-value threshold and expressed optimism about the chances of success, while an Ultragenyx watcher speculated the market was prematurely pricing in study failure.<stembedurl>https://stocktwits.com/RenHenInvestments/message/620415451</stembedurl><stembedurl>https://stocktwits.com/bhavn008/message/620395599</stembedurl>While Ultragenyx’s stock has risen 0.7% so far in 2025, Mereo’s stock&nbsp;has declined 14% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ultragenyx (RARE) and Mereo BioPharma (MREO) slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 as initially planned/ Photo credit: Getty Images

Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.

Equity

The companies now expect final data from the Orbit and Cosmic studies by the end of the year.

Ultragenyx Posts New Data From Bone Disease Study

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating...

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Mereo BioPharma Group (MREO, $3.41) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that MREO's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Needham & Company LLC Boosts Mereo BioPharma Group (NASDAQ:MREO) Price Target to $6.00

Mereo BioPharma Group (NASDAQ:MREO - Free Report) had its price target lifted by Needham & Company LLC from $5.00 to $6.00 in a report published on Thursday, Benzinga reports. Needham & Company LLC...

Mereo BioPharma Group plc (MREO, $3.3) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling MREO's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group (NASDAQ:MREO) Price Target Raised to $6.00

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report) had its target price hoisted by equities research analysts at Needham  Company LLC from $5.00 to $6.00 in a research report issued on...

Mereo BioPharma Group (MREO, $3.02) RSI Indicator left the oversold zone on March 27, 2024

This is a signal that MREO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results

Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024Related Stocks: MREO...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MREO News

MREOMereo Biopharma